Get the Stockscreener App
3.21
1.23%
-0.04
Liminatus Pharma Inc stock is traded at $3.21, with a volume of 15,811.
It is down -1.23% in the last 24 hours and down -8.55% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
See More
Previous Close:
$3.25
Open:
$3.295
24h Volume:
15,811
Relative Volume:
0.75
Market Cap:
$4.31M
Revenue:
Net Income/Loss:
$-11.00M
P/E Ratio:
-8.1143
EPS:
-0.3956
Net Cash Flow:
$-11.99M
1W Performance:
-13.01%
1M Performance:
-8.55%
6M Performance:
-65.41%
1Y Performance:
-94.69%
1-Day Range:
$3.21
$3.3642
1-Week Range:
$3.21
$3.82
52-Week Range:
$3.21
$141.50
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
3.21 | 4.31M | 0 | -11.00M | -11.99M | -0.3956 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Liminatus Pharma Inc Stock (LIMN) Latest News
SkinHealth Systems to Implement 1-for-20 Reverse Stock Split - Yahoo Finance
Form 8K Liminatus Pharma Inc Class A For: 29 September By Investing.com - Investing.com South Africa
Form 8K Liminatus Pharma Inc Class A For: 29 September By Investing.com - Investing.com Nigeria
Form 8K Liminatus Pharma Inc Class A For: 29 September By Investing.com - Investing.com India
Liminatus Pharma, Inc. (LIMN) Stock Price, Chart, News & Analysis - Securities.io
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma selects Synex to advance CAR-T trial - Clinical Trials Arena
Liminatus Pharma selects Synex to advance CAR-T trial - Yahoo
Liminatus engages Synex for IBC101 CAR-T clinical development - Investing.com
Liminatus Pharma Engages Synex Consulting to Support Clinical Development of IBC101 CAR-T Therapy in South Korea - Quiver Quantitative
Liminatus engages Synex for IBC101 CAR-T clinical development By Investing.com - Investing.com UK
Korea’s Ministry of Food and Drug Safety authorizes Liminatus study - Stock Titan
Longeveron Announces 1-for-10 Reverse Stock Split - Yahoo Finance
Nasdaq Orders Immediate Suspension of Flash Sports & Media Stock - minichart.com.sg
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com India
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com UK
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus (NASDAQ: LIMN) turns to 1-for-50 split as Nasdaq listing hangs on $1 bid - Stock Titan
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusChannel Projection - dars.gov.et
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportPullback Trade - dars.gov.et
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Canada
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Australia
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
These stocks are moving in today's pre-market session - ChartMill
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointFear Greed Extreme - vinanet.vn
Liminatus Pharma Inc Stock (LIMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):